I think you and are on the same page here so I'm going to post this again.
So here we are thinking of sales coming for psoriasis and the sublingual tablet. Then Dr. Hirsch gets appointed active chairman. If you don't know the difference between a chairman and CEO I suggest you google it, because there is a difference. But I feel something could be coming we least expected here?? Read my thoughts and come to your own conclusions. Another person on the other board recognized this also.
The most interesting thing I've found about our new chairman, is the company he's with FOMX, is in a phase 3 trial for acne that just failed in march. From what I've read the company still hasn't declared a clear path of moving forward to get past the trial. I think most investors know when OWCP announced the cream could be used for other uses that acne was one one of them, it just hasn't been officially announced. FOMX also has ties to Bayer with there drug, and other dermatology drugs FOMX has.
Long story short here, connect the dots, I think we've found a partner in getting our acne cream out to the world..... something none of us seen coming.
This is just my opinion, but makes a lot of sense.
News 
Market Data 
Discover 
